Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R2 | Q9NPC1 | 11/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6629369 | 0.88 | ALDH1A1 (0.39) | LTB4R2MEN1KMT2ARIPK1PTGDR2 | |
| SCHEMBL2158006 | 0.87 | RIPK1 (0.41) | LTB4R2MEN1KMT2ARIPK1TP53 | |
| SCHEMBL12464658 | 0.87 | LTB4R2 (0.39) | LTB4R2RIPK1PTGDR2TP53HCRTR1 | |
| SCHEMBL2158059 | 0.85 | RIPK1 (0.40) | LTB4R2MEN1KMT2ARIPK1TP53 | |
| SCHEMBL2157862 | 0.84 | MEN1 (0.45) | LTB4R2MEN1KMT2ATP53HCRTR1 | |
| SCHEMBL2157764 | 0.83 | MEN1 (0.44) | LTB4R2MEN1KMT2ATP53 | |
| SCHEMBL2158523 | 0.80 | LTB4R2 (0.44) | LTB4R2MEN1KMT2ARIPK1 | |
| SCHEMBL12464439 | 0.79 | NOS1 (0.41) | TP53 | |
| SCHEMBL3809097 | 0.78 | LTB4R2 (0.41) | LTB4R2MEN1KMT2ARIPK1PTGDR2 | |
| SCHEMBL2157848 | 0.78 | RAB9A (0.48) | LTB4R2MEN1KMT2APTGDR2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7985769-B2 | Compounds and methods for the treatment or prevention of Flavivirus infections | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-26 | — | — | US | disclosed |
| US-7985769-B2 | Compounds and methods for the treatment or prevention of Flavivirus infections | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-26 | — | — | US | disclosed |
| US-20060142347-A1 | Compounds and methods for the treatment or prevention of Flavivirus infections | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2006-06-29 | — | — | US | disclosed |
| US-6881741-B2 | Compounds and methods for the treatment or prevention of Flavivirus infections | VIROCHEM PHARMA INC. (CA) | 2005-04-19 | — | — | US | disclosed |
| EP-1401825-A2 | THIOPHENE DERIVATIVES AS ANTIVIRAL AGENTS FOR FLAVIVIRUS INFECTION | Shire Biochem Inc. (CA) | 2004-03-31 | — | — | EP | disclosed |
| WO-2002100851-A2 | THIOPHENE DERIVATIVES AS ANTIVIRAL AGENTS FOR FLAVIVIRUS INFECTION | SHIRE BIOCHEM INC. (CA) | 2002-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142347-A1 | Compounds and methods for the treatment or prevention of Flavivirus infections | HAVCR2, ZC3HAV1, MAVS | LTB4R2 3225/4885MEN1 3052/4885KMT2A 3270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.